Fernand Labrie
Publications
Page 3 of 8, showing 50 records out of 361 total, starting on record 101, ending on 150
| Publication | Category | Year |
|---|---|---|
| 261. Chen, C., Li, X., Singh, S.M., Bélanger, A., Labrie, F. (1996) Additive in vivo growth-inhibitory effects of Flutamide and Finasteride on androgen-sensitive Shionogi 115 carcinoma. Endocrine-Related Cancer, 3: 217-227. | Prostate Cancer | 1996 |
| 260. Chen, C., Poulin, R., Labrie, F. (1996) Large Shionogi tumors lose their responsiveness to Flutamide treatment. J. Steroid Biochem. Mol. Biol., 58: 489-494. | Prostate Cancer | 1996 |
| 259. Cusan, L., Gomez, J.L., Diamond, P., Candas, B., Labrie, F. (1996) Combined androgen blockade with GnRH analogues and Flutamide at all stages of prostate cancer (Chapter 15), in: Filicori, M. et Flamigni, C., eds: Treatment with GnRH Analogs: Controversies and Prospectives, New-York, The Parthenon Publishing Group, pp 125-137. | Prostate Cancer | 1996 |
| 258. Dufort, I., Soucy, P., Labrie, F., Luu-The, V. (1996) Molecular cloning of human type 3 3?-hydroxysteroid dehydrogenase that differs from 20??hydroxysteroid dehydrogenase by seven amino acids. Biochem. Biophys. Res. Commun., 228: 474-479. | Prostate Cancer | 1996 |
|
257. Labrie, C., Flamand, M., Bélanger, A., Labrie, F. (1996) High bioavailability of DHEA administered percutaneously in the rat. J. Endocrinol., 150: S107-S118. Attached files: LabrieC(1996)High bioavailabiltiy of dehydro....pdf |
Prostate Cancer | 1996 |
| 256. Labrie, F., Bélanger, A., Cusan, L., Labrie, C., Simard, J., Luu-The, V., Gomez, J.L., Diamond, P., Candas, B. (1996) History of LHRH agonist and combination therapy in prostate cancer. Endocrine-Related Cancer, 3: 243-278. | Prostate Cancer | 1996 |
| 255. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Cusan, L., Gomez, J., Diamond, P., Candas, B. (1996) Sources d'androgènes chez l'homme et traitement hormonal du cancer de la prostate (Chapter 16), in: Belaisch, J., Drodowsky, M.A. et Vermeulen, A., eds: Progrès en Andrologie: Endocrinologie Masculine, Doin, pp 215-229. | Prostate Cancer | 1996 |
| 254. Labrie, F., Candas, B., Cusan, L., Diamond, P., Gomez, J.L. (1996) Antiandrogen story erred [Letter to the Editor]. The Medical Post, 32: | Prostate Cancer | 1996 |
|
253. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M. (1996) Diagnosis of advanced or non-curable prostate cancer can be practically eliminated by prostate-specific antigen. Urology, 47: 212-217. Attached files: LabrieF(1996)Diagnosis of advanced or noncurable.....pdf |
Prostate Cancer | 1996 |
| 252. Labrie, F., Cusan, L., Dupont, A., Gomez, J.-L., Simard, J., Luu-The, V., Pelletier, G., Labrie, C., Bélanger, A. (1996) Androgen receptor antagonists (Chapter 28), in: Adashi, E.Y., Rock, J.A. et Rosenwaks, Z., eds: Reproductive Endocrinology, Surgery and Technology, Philadelphia, Lippincott-Raven Publishers, pp 559-583. | Prostate Cancer | 1996 |
| 251. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Bélanger, A., Candas, B. (1996) Combination therapy in localized prostate cancer (Chapter 4), in: Schroder, F.H., ed. Recent Advances in Prostate Cancer and BPH, Parthenon Publishing, pp 31-43. | Prostate Cancer | 1996 |
| 250. Labrie, F., Dupont, A., Cusan, L., Gomez, J.L., Surubu, R., Diamond, P. (1996) Combination therapy with Flutamide: The therapy of choice from early to advanced stages of prostate cancer, in: Denis, L., ed. Antiandrogens in Prostatic Cancer, Italy, European School of Oncology, pp 63-74. | Prostate Cancer | 1996 |
| 249. Labrie, F., Simard, J., Luu-The, V., Labrie, C., Bélanger, A. (1996) Adrenal androgens are responsible for 40-50% and not 5-10% of total prostatic androgens in 65-year-old men: intracrinology, in First International Consultation on Prostate Cancer, Monaco, pp Published on CD-ROM. | Prostate Cancer | 1996 |
|
248. Luo, S., Martel, C., Leblanc, G., Candas, B., Singh, S.M., Labrie, C., Simard, J., Bélanger, A., Labrie, F. (1996) Relative potencies of flutamide and casodex: preclinical studies. Endocrine-Related Cancer, 3: 229-241. Attached files: LuoS(1996)Relative Potencies of Flutamide....pdf |
Prostate Cancer | 1996 |
| 247. Vaillancourt, L., Têtu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Suburu, R.E., Diamond, P., Candas, B., Labrie, F. (1996). Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study. Am. J. Surg. Pathol., 20: 86-93. | Prostate Cancer | 1996 |
|
246. van der Kwast, T.H., Tetu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Diamond, P., Labrie, F. (1996) Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Prostate, 28: 227-231. Attached files: Van der KwastTH(1996)Androgen receptor modulation in ......pdf |
Prostate Cancer | 1996 |
| 245. Bélanger, A., Van Halbeek, H., Graves, H.C.B., Grandbois, K., Stamey, T.A., Lihua, H., Poppe, I., Labrie, F. (1995) Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate, 27: 187-197. | Prostate Cancer | 1995 |
| 244. Chen, C., Puy, L.A., Simard, J., Li, X., Singh, S.M., Labrie, F. (1995) Local and systemic reduction by topical Finasteride or Flutamide on hamster flank organ size and enzyme activity. J. Invest. Dermatol., 105: 678-682. | Prostate Cancer | 1995 |
| 243. Labrie, F. (1995) Endocrine therapy of prostate cancer: optimal form and timing. J. Clin. Endocrinol. Metab., 80: 1066-1071. | Prostate Cancer | 1995 |
| 242. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C. (1995) Intracrinologie: autonomie et liberté des tissus périphériques. Ann. Endocrinol. (Paris), 56: 23-29. | Prostate Cancer | 1995 |
| 241. Labrie, F., Crawford, D.; (1995) Anti-androgens in treatment of prostate cancer. Lancet, 346: 1030-1031. | Prostate Cancer | 1995 |
| 240. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Candas, B. (1995) Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality. J. Clin. Endocrinol. Metab., 80: 2002-2013. | Prostate Cancer | 1995 |
| 239. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Candas, B. (1995) Screening und Re-Screening des Prostatakarzinoms: Die Quebec-Studie, in Faul, P. et Altwein, J.E., eds: Screening des Prostatakarzinoms, Berlin, Springer-Verlag, pp 339-352. | Prostate Cancer | 1995 |
| 238. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Candas, B. (1995) Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy. Cancer Surv. 23: 149-156. | Prostate Cancer | 1995 |
| 237. Li, X., Singh, S.M., Côté, J., Laplante, S., Veilleux, R., Labrie, F. (1995) Synthesis and in vitro evaluation of 4-substituted-N-(1,1-dimethylethyl)-3-oxo-4-androsten-17?-carboxamides as 5?-reductase inhibitors and antiendrogens. J. Med. Chem., 38: 1456-1461. | Prostate Cancer | 1995 |
| 236. Li, X., Singh, S.M., Labrie, F. (1995) Synthesis and in vitro activity of 17?-(N-alkyl)formamido/ alkylamido-4-aza-/4-methyl-4-aza-3-oxo-5?-androstan-3-ones as inhibitors of human 5?-reductase and antagonists on the androgen receptor. J. Med. Chem., 38: 1158-1173. | Prostate Cancer | 1995 |
| 235. Li, X., Singh, S.M., Lourdusamy, M., Mérand, Y., Veilleux, R., Labrie, F. (1995) Synthesis and in vitro antiandrogenic activity of 17?-hydroxy-17?-(w-hydroxy/haloalkyn-1'-yl)-4-methyl-4-aza-3-oxo-5?-androstan-(1-ene)-3-ones. Bioorg. Med. Chem. Lett., 5: 1061-1064. | Prostate Cancer | 1995 |
| 234. Narod, S., Dupont, A., Cusan, L., Diamond, P., Gomez, J.L., Suburu, R., Labrie, F. (1995) The impact of family history on early detection of prostate cancer. Nature Medicine, 1: 99-101. | Prostate Cancer | 1995 |
| 233. Sun, S., Narod, S., Aprikian, A., Ghadirian, P., Labrie, F. (1995) Androgen receptor and familial prostate cancer. Nature Medicine, 1: 848-849. | Prostate Cancer | 1995 |
| 232. Bélanger, A., Candas, B., Dupont, A., Cusan, L., Diamond, P., Gomez, J.L., Labrie, F. (1994) Changes in serum concentration of conjugated and unconjugated steroids in 40- to 80-year old men. J. Clin. Endocrinol. Metab., 79: 1086-1090. | Prostate Cancer | 1994 |
| 231. Cusan, L., Gomez, J.L., Dupont, A., Diamond, P., Lemay, M., Moore, S., Labrie, F. (1994) Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide. Prostate, 24: 257-261. | Prostate Cancer | 1994 |
| 230. Koutsilieris, M., Dupont, A., Gomez, J.L., Cusan, L., Suburu, R., Diamond, P., Labrie, F. (1994) Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormonal therapy (GnRH-A plus Flutamide). Anticancer Res., 14: 627-634. | Prostate Cancer | 1994 |
| 229. Labrie, F. (1994) Intracrinology and Cancer Therapy. Science Watch, 5: 3-4. | Prostate Cancer | 1994 |
| 228. Labrie, F. (1994) Les antiandrogènes dans le cancer de la prostate. La Lettre du Pharmacologue, 8: 190-195. | Prostate Cancer | 1994 |
| 227. Labrie, F. (1994) Prostate cancer [Letter to the Editor: Reply to 342: 901-5, 1993]. Lancet, 343: 491. | Prostate Cancer | 1994 |
| 226. Labrie, F. (1994) Prostate cancer [Letter to the Editor: Reply to Cheney re 343: 491-2, 1994]. Lancet, 343: 976-977. | Prostate Cancer | 1994 |
| 225. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Candas, B. (1994) Downstaging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with Flutamide and a luteinizing hormone-releasing hormone agonist. Urology, 44: 29-37. | Prostate Cancer | 1994 |
| 224. Labrie, F., Simard, J., Bélanger, A., Luu-The, V., Labrie, C. (1994) Molecular biology of the intracrine steroidogenic enzymes in the human prostate, in: Motta, M. et Serio, M., eds: Sex Hormones and Antihormones in Endocrine-Dependent Pathology: Basic and Clinical Aspects, New York, Elsevier, pp 77-92. | Prostate Cancer | 1994 |
| 223. Sugimoto, K., Simard, J., Veilleux, R., Haagensen, D.E., Labrie, F. (1994) Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells. J. Steroid Biochem. Mol. Biol., 51: 167-174. | Prostate Cancer | 1994 |
| 222. Bélanger, A., Rong, P.M., Liu, S., Lavoie, L., Labrie, F. (1993) Characterization and measurement of prostate-specific antigen using monoclonal antibodies. Clin. Invest. Med., 16: 409-415. | Prostate Cancer | 1993 |
| 221. Dupont, A., Cusan, L., Gomez, J.L., Koutsilieris, M., Suburu, R., Emond, J., Labrie, F. (1993) Combination therapy with Flutamide and the LHRH agonist [D-Trp6-des-Gly-NH2]LHRH ethylamide in stage C prostatic carcinoma. Br. J. Urol., 72: 629-634. | Prostate Cancer | 1993 |
| 220. Dupont, A., Gomez, J.L., Cusan, L., Koutsilieris, M., Labrie, F. (1993) Response to Flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol., 150: 908-913. | Prostate Cancer | 1993 |
| 219. Labrie, F. (1993) GNRH agonists in prostate cancer, in GnRH analogues - The State of the Art 1993, New York, Parthenon Publishing, pp 103-121. | Prostate Cancer | 1993 |
| 218. Labrie, F. (1993) Intracrinology: its impact on prostate cancer. Curr. Opin. Urol., 3: 381-387. | Prostate Cancer | 1993 |
| 217. Labrie, F. (1993) Mechanism of action and pure antiandrogenic properties of Flutamide. Cancer, 72: 3816-3827. | Prostate Cancer | 1993 |
| 216. Labrie, F. (1993) Non-steroidal antiandrogens, in: Droz, J.P., Cvitkovic, E., Armand, J.P. et Khoury, S., eds: Handook of Chemotherapy in Clinical Oncology, London, Scientific Communication International Ltd., pp 389-391. | Prostate Cancer | 1993 |
| 215. Labrie, F. (1993) Present status of endocrine therapy of prostate cancer. Eur. Urol. Today, 3: 10-11. | Prostate Cancer | 1993 |
| 214. Labrie, F., Bélanger, A., Dupont, A., Luu-The, V., Simard, J., Labrie, C. (1993) Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med., 16: 475-492. | Prostate Cancer | 1993 |
| 213. Labrie, F., Bélanger, A., Simard, J., Labrie, C., Dupont, A. (1993) Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first line therapy. Cancer, 71: 1059-1067. | Prostate Cancer | 1993 |
| 212. Labrie, F., Dupont, A., Cusan, L., Gomez, J.-L., Diamond, P. (1993) Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer. Clin. Invest. Med., 16: 493-498. | Prostate Cancer | 1993 |